Cat. No. 0619
Chemical Name: (E)-2-Cyano-3-(3,4-dihydroxyphenyl)
Biological ActivityPotent inhibitor of epidermal growth factor receptor (EGFR) kinase (IC50 = 0.7 μM). Selective over ErbB2, PDGFR and insulin receptor kinase (IC50 values are 42, 6 and > 100 μM respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Tomlins et al (2005) Cross-talk between the calcium-sensing receptor and the epidermal growth factor receptor in Rat-1 fibroblasts. Exp.Cell Res. 308 439. PMID: 15950968.
Ben-Bassat et al (1999) Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J.Pharmacol.Exp.Ther. 290 1442. PMID: 10454524.
Gazit et al (1991) Tyrphostins. 2. Heterocyclic and α-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896. PMID: 1676428.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses AG 494 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: AG 494, supplier, Potent, EGFR, kinase, inhibitors, inhibits, Epidermal, Growth, Factors, Receptors, ErbB, Her, Tyrosine, Kinases, RTKs, AG494, Tocris Bioscience, EGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.